

# Dosing guide for PANCREAZE 37,000

Is your patient a candidate for PANCREAZE 37,000?

**PANCREAZE 37,000** can be a convenient, appropriate dose for many EPI patients — **minimizing the number of capsules they take daily.** 

#### Indication

PANCREAZE is indicated for the treatment of exocrine pancreatic insufficiency in adult and pediatric patients.

#### **Important Safety Information**

Fibrosing Colonopathy: Associated with high doses, usually over prolonged use and in pediatric patients with cystic fibrosis.

### Dosing PANCREAZE 37,000<sup>1</sup>

Prescribe **PANCREAZE** for both meals and snacks — make sure to I specify the number of capsules that should be taken per meal and per snack. All 6 doses of **PANCREAZE** use a phthalate-free formulation.<sup>2</sup>

Patient Weight (Ibs)	Minimum Dose Per Snack	Minimum Dose Per Meal	Maximum Dose Per Meal	Individualized Dosing
110 to 130	Tvus	Tvus	Tivus Tivus Tivus	Dose should be individualized based on age, weight, clinical symptoms, degree of steatorrhea and fat content of diet.  Usually, half of the prescribed dose for an individualized full meal should be given with each snack.
131 to 163	Tvus	Tvus	Int 37 In	
164 to 195	Tivus	Avus Avus	Int 37 In	
196 to 228	Tivus	Tivus Tivus	/r 37	PANCREAZE 37,000 may not be appropriate for all patients. PANCREAZE is also available in 2,600, 4,200, 10,500, 16,800 and 21,000 lipase unit capsules.
≥ 229	TVUS	Ivus Ivus	1 37   1 37	
This chart is intended as a guide only. Capsules shown are not actual size and represent nearest pill			<ul> <li>Do not substitute other pancreatic enzyme products for PANCREAZE.</li> </ul>	

- count within the recommended range.
- **PANCREAZE** should be initiated at the lowest recommended dose and gradually increased.
- For children 4 years and older and adults, dosing should begin with 500 lipase units/kg of body weight per meal up to a maximum of 2,500 lipase units/kg of body weight per meal.
- Patients weighing <110 lbs may require a lower lipase unit starting dose. Patients weighing >230 lbs may require a higher lipase unit starting dose and have a higher per-meal maximum dose.
- Doses greater than 6,000 lipase units/kg of body weight per meal have been associated with colonic strictures, indicative of fibrosing colonopathy, in children with cystic fibrosis less than 12 years of age.

#### **Important Safety Information**

Colonic stricture reported in pediatric patients less than 12 years of age with dosages exceeding 6,000 lipase units/kg/meal. Monitor during treatment for progression of preexisting disease. Do not exceed the recommended dosage, unless clinically indicated.

Hyperuricemia has been reported with high dosages; consider monitoring blood uric acid levels in patients with gout, renal impairment, or hyperuricemia.

Irritation of the oral mucosa may occur due to loss of protective enteric coating on the capsule contents.

#### **Important Safety Information**


The presence of porcine viruses that might infect humans cannot be definitely excluded.

Monitor patients with known reactions to proteins of porcine origin. If symptoms occur, initiate appropriate medical management; consider the risks and benefits of continued treatment.

## PANCREAZE 37,000 Prescribing Scenario

## Prescribe **PANCREAZE** for both meals and snacks.<sup>1</sup>

Scenario: 175lb patient's dose titrated to provide 1,000 lipase units/kg/meal based on symptoms and diet (79,365 USP lipase units per meal).



- Mealtime dose can vary based on symptoms and the fat content and volume of the meal ingested.
- Please review the appropriate doses for your patient's individual dietary needs. See the dosing chart inside.

For additional product information please visit:

### **HCP.PANCREAZE.com**



**References: 1.** PANCREAZE Full Prescribing Information. Campbell, CA: VIVUS LLC; 2024. **2.** Cystic Fibrosis Foundation. (n.d.). Phthalates. Retrieved from https://www.cff.org/phthalates

#### **Important Safety Information**

Please read the accompanying **PANCREAZE Medication Guide** and **Full Prescribing Information**.

©2024 VIVUS LLC.All rights reserved. 500187.07-USP 07/2024



